
News|Articles|October 1, 2006
Pipeline Preview (October 2006)
Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer
Advertisement
Recommendations for approval
Recommendations against approval
Nonapprovable designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
5
































